Published in Biotech Business Week, May 19th, 2003
The parties plan to use Medarex's UltiMAb technology to generate fully human antibodies to SARS.
Under the terms of the agreement, Medarex and MBL expect to share equally the development costs of any antibody products as well as any future revenues arising from these products.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.